Mesothelin-ODC422-461 fusion protein expressed by DCs (dendritic cells) and application of mesothelin-ODC422-461 fusion protein

The invention discloses a mesothelin-ODC422-461 fusion protein expressed by DCs (dendritic cells) and application of the mesothelin-ODC422-461 fusion protein. The fusion protein is a protein consisting of an amino acid sequence as shown in SEQ ID NO. 1, and is formed by fusing the mesothelin protein and amino acid at site C-422-461 of mouse ornithine decarboxylase, and the DCs are derived from DCs differentiated from monocyte in PBMCs, DCs differentiated from iPS/ES induction, and primary DC cells separated from blood. The fusion protein can be used for inducible expression in DC cells, tumor antigen presentation of the DCs is facilitated, the antigen presentation efficiency of in-vivo T cells is improved, the T cells are activated to kill tumor cells, and in addition, the fusion protein can be used for cell therapy since the half-life period of the fusion protein is very short, the fusion protein serving as medicine has small toxicity and small side effects, and can generate synergistic effects with immune c